Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07222332 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

Name: A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) — clinical trial record (NCT07222332)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorEli Lilly and Company

Started2026-02-05

View on ClinicalTrials.gov ↗

The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.

Amendment history 1 change detected by DataLookout

2026-07-21

Trial sites expanded: 133 → 136 locations

Trial Details

NCT Number	NCT07222332
Lead Sponsor	Eli Lilly and Company
Conditions	Diabetes Mellitus, Type 1
Enrollment	300 participants
Start Date	2026-02-05
Primary Completion	2028-07 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-09-04